Driving Innovation:
V||V Healthcare's Long-Acting Pipeline
Assets in development target multiple stages of the
HIV life cycle with expanded dosing options
Binding & Fusion
X
Binding & Fusion1
Class: Broadly Neutralising Antibodies (bNAbs)
- Lotivibart (VH3810109) – Phase IIb
- Bibliography
Nuclear Entry & Uncoating
X
Nuclear Entry & Uncoating2,3
Class: Capsid Inhibitors
- VH4011499 – Phase II
- VH4770359 – Phase I
- Bibliography
Integration
X
Integration4-8
Class: Integrase Inhibitors
- CAB 1600 (PrEP) – Phase II
- CAB 1600 (Treatment) – Phase III
- VH4524184 – Phase II
- VH4367310 – Phase I
- Bibliography
Assembly & Budding
X
Assembly & Budding2,3
Class: Capsid Inhibitors
- VH4011499 - Phase II
- VH4770359 - Phase I
- Bibliography
1Binding and Fusion1
Class: Broadly Neutralising Antibodies (bNAbs)
- Lotivibart (VH3810109) – Phase IIb
- Bibliography
2Nuclear Entry & Uncoating2,3
Class: Capsid Inhibitors
- VH4011499 – Phase II
- VH4770359 – Phase I
- Bibliography
3Integration4-8
Class: Integrase Inhibitors
- CAB 1600 (PrEP) – Phase II
- CAB 1600 (Treatment) – Phase III
- VH4524184 – Phase II
- VH4367310 – Phase I
- Bibliography
4Assembly and Budding2,3
Class: Capsid Inhibitors
- VH4011499 - Phase II
- VH4770359 - Phase I
- Bibliography
- Rolle et al. CROI 2026; Denver, CO. Oral presentation 178.
- Thakkar et al. CROI 2026; Denver, CO. Oral presentation 175.
- NCT07525544. Available at: https://clinicaltrials.gov. Accessed August 2026.
- Castronova et al. CROI 2026; Denver, CO. Poster 495.
- Han et al. CROI 2024; Denver, CO. Oral Presentation 130.
- Back et al. CROI 2026; Denver, CO. Oral Presentation 176.
- Baker M et al. AIDS 2024; Poster WEPEA028.
- NCT07818915. Available at: https://clinicaltrials.gov. Accessed September 2026.
Figure adapted from: ViiV Healthcare meet the management: Getting ahead of HIV together, 2023